Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.
about
Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancerThe mammary stem cell hierarchy: a looking glass into heterogeneous breast cancer landscapesNovel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibitionGenomic profiling in triple-negative breast cancerMolecular subtypes and imaging phenotypes of breast cancer.Key Players in Choline Metabolic Reprograming in Triple-Negative Breast CancerAndrogen Receptor: A Complex Therapeutic Target for Breast CancerTriple-negative breast cancer: is there a treatment on the horizon?Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes.MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ERα)-positive mammary adenocarcinomas.Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Contribution of p53 to metastasis.Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapyA pan-cancer proteomic perspective on The Cancer Genome Atlas.TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation statusPreliminary characterization of IL32 in basal-like/triple negative compared to other types of breast cell lines and tissues.How many etiological subtypes of breast cancer: two, three, four, or more?Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of originPredicting response and survival in chemotherapy-treated triple-negative breast cancer.Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Standard of care and promising new agents for triple negative metastatic breast cancerPharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway.Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.Triple-negative breast cancer: new perspectives for targeted therapies.Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancerDifferentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models.Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.Defining breast cancer intrinsic subtypes by quantitative receptor expression.Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues.Development and verification of the PAM50-based Prosigna breast cancer gene signature assayLow spinophilin expression enhances aggressive biological behavior of breast cancer.
P2860
Q21132473-DC952543-9A64-4919-A442-F2EF1C18878FQ26799993-06C0F0BC-388C-4FAE-83DC-7ED184AFC053Q26851765-1B4DD3F4-50C9-442D-BBAF-2CA4EA4BE51EQ27015775-587E159B-CE61-4F5A-B5BF-A53FB2851DEFQ28069885-BF33AAF6-547E-403A-898C-68AA3011D1F9Q28074613-891B7BE8-CB17-45D8-8F80-D5D09E9EF3D2Q28075188-4D1C49DC-1D8C-40B7-9467-A78F75A66F3EQ28077243-43F7E84F-FF7E-4EB2-A4E8-57DC0F993D74Q28085062-2B4B36DF-FE57-4CBB-9FEE-8DD23D9FC726Q33416887-3D62FD82-2291-4E98-9D68-B814BCCEE8DAQ33589487-40EC406D-847E-40FE-B673-A0170F07F98FQ33657478-0A22A2B7-1E82-4D4D-9131-B381D3BACDD3Q33739184-16EA6E61-F0FA-4874-A25D-9143AA6EBF34Q33769821-C295B75E-765D-4AA0-A8AE-6E686A9DAA53Q33776331-AEA0B2B6-9817-4842-9F71-A58FA8679B9AQ33873330-34A0A3B7-B7F7-4319-932D-CB0352873B07Q33944976-AFD53B4B-C926-44CC-953F-2FADAA1807F8Q33954557-92751F47-E0A0-45CA-B0C3-9B48D731D648Q34038170-5D843AAA-43DF-441C-B638-BF0EBE1A7B7CQ34042748-3FFD0EBA-FCA8-4744-8B02-BD12280D6110Q34106175-6F93A438-FC3D-402B-894E-C4D843C2D523Q34123261-B9F99C08-E040-4322-9AC7-F70198CED07EQ34354538-D3DF7B04-E539-4FED-B2AA-44EF251EF3C6Q34476337-CDAF4C62-BC7F-4231-90EF-931478E86C33Q34774884-2C90A835-0B5E-4C0B-AACD-CD462D24089DQ34978420-55F09988-4E07-4D8F-913B-242C82C54FCBQ35000293-4FA5ADE1-DE27-4565-B886-8A522B4AB05AQ35000673-7ED436ED-43D2-4C66-B432-86CA43C8C41CQ35001758-4E9D0DE1-4608-4763-BAD9-3CA02239A34FQ35007438-84959EDB-3FF0-4D4F-AA53-8F095B94C9C6Q35025741-80F38A1B-0026-4655-8D19-7635240F9B27Q35079683-D33CB218-EA0B-4628-B95E-E90E030C95B8Q35185688-71AFC32B-F4C7-4CBE-B38D-AA473D556020Q35314135-3E446B82-07A7-49F0-8942-5D9630ED17AFQ35374807-D9D557BA-0DF2-40B0-8D24-27648EB88698Q35550054-F62E8BCD-5F82-4C4B-9FB8-5EC374566AE7Q35586697-A40AF7F2-71E6-42B8-A229-BBA2FDC564DFQ35593154-4A8730BC-278B-43B8-ACBE-61A892E041BDQ35752868-A176A6C3-07DA-4EF3-AC86-17DEDE61953DQ35793756-A0C8C70D-11A2-412F-AB36-D58B6AC95154
P2860
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Molecular characterization of ...... triple-negative breast cancer.
@ast
Molecular characterization of ...... triple-negative breast cancer.
@en
type
label
Molecular characterization of ...... triple-negative breast cancer.
@ast
Molecular characterization of ...... triple-negative breast cancer.
@en
prefLabel
Molecular characterization of ...... triple-negative breast cancer.
@ast
Molecular characterization of ...... triple-negative breast cancer.
@en
P2093
P2860
P50
P1433
P1476
Molecular characterization of ...... triple-negative breast cancer.
@en
P2093
Barbara Adamo
Carey K Anders
Lisa A Carey
P2860
P304
P356
10.1634/THEONCOLOGIST.2012-0397
P577
2013-02-12T00:00:00Z